1
                                                                     EXHIBIT 99


RESPONSE ONCOLOGY, INC. ANNOUNCES
APPOINTMENT OF NEW DIRECTOR


MEMPHIS, TENNESSEE (January 3, 1996) -- Response Oncology, Inc. today
announced the appointment of Leonard A. Kalman, M.D. to its Board of Directors. 
Dr. Kalman, a co-medical director of the Baptist Hospital of Miami Regional
Cancer Center, is a practicing oncologist with the Oncology Hematology Group of
South Florida, P.A. (the "Group").  Dr. Kalman is a graduate of Wesleyan
University, and the Duke University School of Medicine.  Among his other
appointments, Dr. Kalman was a fellow in medical oncology at the Memorial Sloan
Kettering Cancer Center in New York.  He has been in private practice in Miami,
Florida since 1982.

In a separate statement, the Company announced that it has acquired the assets
of, and entered into a long-term management services agreement with the Group. 
The Group is the Company's first physician group under such a practice
management relationship.  The Company has plans to establish additional
relationships of this nature in the future.

The Company also announced that it has named Joseph T. Clark as Chief Executive
Officer of the Company in addition to his duties as President.  This will allow
the Company's Chairman, William H. West, M.D., to concentrate on medical and
scientific affairs of the Company, particularly in connection with refining
disease management capabilities to support managed care marketing.  Mr. Clark
has served as President of the Company since 1993.

Dr. West stated "We are very pleased to add Dr. Kalman to our Board of
Directors.  We believe that he will be very valuable in helping to guide the
Company's physician practice management strategy.  Further, we believe that Mr.
Clark's appointment to the position of CEO is appropriate as the Company's
business plans evolve to include oncology practice management services and
cancer care networks."

Response Oncology is a comprehensive cancer management company which owns
and/or operates a network of outpatient treatment centers, or IMPACT(R)
Centers, which provide stem cell supported high dose chemotherapy and other
advanced cancer treatment services under the direction of practicing
oncologists; owns the assets of and manages oncology practices; and conducts
clinical cancer research on behalf of pharmaceutical manufacturers.  Over 300
medical oncologists are affiliated with the Company.

The common stock of Response Oncology, Inc. is traded on the NASDAQ National
Market under the symbol ROIX.


                                  * * * * *